Mark Rodeghier

Mark Rodeghier

Auto-generated profile, based on publicly available information

Mark Rodeghier

Rodeghier Consultants Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2019 in Blood
Verified
Journal Article
Closed access
PDF file
MDMichael DeBaun
Michael DeBaun
DGDjamila L. Ghafuri
Djamila L. Ghafuri
MRMark Rodeghier
Mark Rodeghier
PMPoulami Maitra
Poulami Maitra
SCShruti Chaturvedi
Shruti Chaturvedi
KAKenneth I. Ataga
Kenneth I. Ataga

20 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
AKAdetola A Kassim
Adetola A Kassim
JFJosu de la Fuente
Josu de la Fuente
ENErfan Nur
Erfan Nur
KWKarina L. Wilkerson
Karina L. Wilkerson
AAAli D. Alahmari
Ali D. Alahmari
MDMichael DeBaun
Michael DeBaun
In the setting of a learning collaborative, we conducted an international multicenter phase 2 clinical trial testing the hypothesis that nonmyeloablative–related haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will result in 2-year event-free survival (no graft failure or death) of at least 80%. A total of 70 participants were evaluable based on the conditioning protocol. Graft failure occurred in 8 of 70 (11.4%) and only in participants aged <18 years; all had autologous reconstitution. After a median follow-up of 2.4 years, the 2-year Kaplan-Meier–based probability of event-free survival was 82.6%. The 2-year overall survival was 94.1%, with no difference between children and adult participants. After excluding participants with graft failure (n = 8), participants with engraftment had median whole blood donor chimerism values at days +180 and +365 after transplant of 100% (n = 58), respectively, and 96.6% (57/59) were off immunosuppression 1 year after transplant. The 1-year grade 3 to 4 acute graft-versus-host disease (GVHD) rate was 10%, and the 2-year moderate–severe chronic GVHD rate was 10%. Five participants (7.1%) died from infectious complications. We demonstrate that nonmyeloablative haploidentical BMT with thiotepa and PTCy is a readily available curative therapy for most adults, even those with organ damage, compared to the more expensive myeloablative gene therapy and gene editing. Additional strategies are required for children to decrease graft failure rates. The trial was registered at www.clinicaltrials.gov as #NCT01850108.

23 February 2023 in Blood
Verified
Journal Article
Open access
PDF file
SAShehu U. Abdullahi
Shehu U. Abdullahi
SSSurayya Sunusi
Surayya Sunusi
MAMohammed Sani Abba
Mohammed Sani Abba
SSSaifuddeen Sani
Saifuddeen Sani
HIHauwau Aminu Inuwa
Hauwau Aminu Inuwa
MDMichael DeBaun
Michael DeBaun
We tested the hypothesis that fixed oral moderate-dose hydroxyurea (20 mg/kg per day) for initial treatment of secondary stroke prevention results in an 80% relative risk reduction of stroke or death when compared with fixed oral low-dose hydroxyurea (10 mg/kg per day) in a phase 3 double-blind, parallel-group, randomized controlled trial in children with sickle cell anemia (SCA) living in Nigeria. A total of 101 participants were randomly allocated to low-dose (n = 49) and moderate-dose (n = 52) hydroxyurea treatment groups. The median participant follow-up was 1.6 years (interquartile range, 1.0-2.3), with a planned minimum follow-up of 3.0 years. A total of 6 recurrent strokes and 2 deaths vs 5 recurrent strokes and 3 deaths occurred in the low- and moderate-dose groups, respectively. The incidence rate ratio (IRR) of the primary outcome measure of stroke or death in the low- and moderate-dose hydroxyurea treatment groups was 0.98 (95% confidence interval [CI], 0.32-3.00; P = .97). The trial was stopped early owing to no clinical difference in the incidence rates of the primary outcome measure. The incidence rates of recurrent strokes were 7.1 and 6.0 per 100 person-years in the low- and moderate-dose groups, respectively, (IRR, 1.18; 95% CI, 0.30-4.88; P = .74). As a measure of adherence to the oral hydroxyurea therapy, the median percent of returned pills was 3.0% and 2.6% in the low- and moderate-dose groups, respectively. No participant had hydroxyurea therapy stopped for myelosuppression. For children with SCA in low-income settings without access to regular blood transfusion therapy, initial low-dose hydroxyurea is a minimum known efficacious dose for secondary stroke prevention.

14 February 2019 in Journal of Women's Health
Verified
Journal Article
Closed access
DSDeva Sharma
Deva Sharma
MDMelissa E. Day
Melissa E. Day
SSSarah-Jo Stimpson
Sarah-Jo Stimpson
MRMark Rodeghier
Mark Rodeghier
DGDjamila Ghafuri
Djamila Ghafuri
MDMichael DeBaun
Michael DeBaun
Background: Acute vaso-occlusive pain episodes in sickle cell disease (SCD) are associated with increased rates of hospitalization and early mortality. Despite the observation that women have higher rates of acute vaso-occlusive pain episodes than men, sex-specific risk factors for acute vaso-occlusive pain have not been identified. We tested the hypothesis that acute vaso-occlusive pain is temporally associated with the onset of menstruation in women with SCD. Methods: Initially, using a cross-sectional study design, we administered questionnaires, including validated measures of SCD pain frequency and severity within the last 30 days, as well as menstrual symptoms in a discovery group ( n = 103). We then confirmed our findings by administering the same questionnaires online in a replication group ( n = 118). A validated questionnaire was used to define dysmenorrhea. Results: In the initial discovery group, 28% (29 of 103) reported acute vaso-occlusive pain episodes temporally associated with menstruation, and 72% (74 of 103) did not. Of the 29 reporting acute vaso-occlusive pain associated with menstruation, 90% (26) and 10% (3) did and did not meet criteria for dysmenorrhea, respectively. In the replication group, 36% (43 of 118) reported acute vaso-occlusive pain temporally associated with menstruation. Of the 43 reporting acute vaso-occlusive pain associated with menstruation, 60% (26) and 40% (17) did and did not meet criteria for dysmenorrhea, respectively. Conclusions: In both the discovery and replication groups, we demonstrate that acute vaso-occlusive pain is temporally associated with the onset of menstruation that women with SCD can distinguish from dysmenorrhea.

19 November 2018 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
SOSamuel A. Oppong
Samuel A. Oppong
EAEugenia V. Asare
Eugenia V. Asare
EOEdeghonghon Olayemi
Edeghonghon Olayemi
TBTheodore Boafor
Theodore Boafor
YDYvonne Dei-Adomakoh
Yvonne Dei-Adomakoh
MDMichael DeBaun
Michael DeBaun
In Africa, the maternal mortality rate in sickle cell disease (SCD) is ~10%. Our team previously demonstrated an 89% decrease in mortality rate in a before‐and‐after feasibility study among women with SCD living in low‐resource setting in Ghana. In the same cohort including additional participants with and without SCD, we used a prospective cohort design to test the hypothesis that implementing a multidisciplinary care team for pregnant women with SCD in low‐resource setting will result in similar maternal and perinatal mortality rates compared to women without SCD. We prospectively enrolled pregnant women with and without SCD or trait and followed them up for 6‐week postpartum. We tested the newborns of mothers with SCD for SCD. We recruited age and parity matched pregnant women without SCD or trait as the comparison group. Maternal and perinatal mortality rates were the primary outcomes. A total of 149 pregnant women with SCD (HbSS, 54; HbSC, 95) and 117 pregnant women without SCD or trait were included in the analysis. Post‐intervention, maternal mortality rates were 1.3% and 0.9% in women with and without SCD, respectively (P = 1.00); the perinatal mortality rates were 7.4% and 3.4% for women with and without SCD, respectively (P = 0.164). Among the mothers with SCD, ~15% of newborns had SCD. Multidisciplinary care of pregnant women with SCD may reduce maternal and perinatal mortality rates to similar levels in pregnant women without SCD in low‐resource settings. Newborns of mothers with SCD have a high rate of SCD.

1 January 2021 in Pediatric Neurology
Verified
Journal Article
Closed access
ASAlyssa A. Schlotman
Alyssa A. Schlotman
MDManus J. Donahue
Manus J. Donahue
AKAdetola A. Kassim
Adetola A. Kassim
CLChelsea A. Lee
Chelsea A. Lee
SWSpencer L. Waddle
Spencer L. Waddle
LJLori C. Jordan
Lori C. Jordan